Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after announcing the successful completion of a first human trial of its pioneering MicroBlate Flex device for soft tissue lung lesion microwave ablation.
Gulliford reveals the difference he believes the product could ultimately make to people suffering from early-stage lung cancer, saying that he's "really pleased that we've had a great outcome so far."